By Iain Gilbert
Date: Thursday 30 Oct 2025
(Sharecast News) - Pharmaceutical giant Eli Lilly posted stronger-than-expected third-quarter earnings and revenue on Thursday, fuelled by surging demand for its diabetes drug Mounjaro and weight-loss treatment Zepbound.
| Currency | US Dollars |
| Share Price | $ 1,010.31 |
| Closing Price Change | $ -4.18 |
| % Change | 0.00 % |
| 52 Week High | $1,109.94 |
| 52 Week Low | $625.65 |
| Volume | 0 |
| Shares Issued | 948.17m |
| Beta | 0.71 |
| RiskGrade | 179 |
| Strong Buy | 11 |
| Buy | 12 |
| Neutral | 8 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 31 |

| Time | Volume / Share Price |
| 12:28 | 86 @ $996.99 |
| 12:28 | 80 @ $997.03 |
| 12:28 | 40 @ $997.03 |
| 12:28 | 67 @ $997.00 |
| 12:28 | 88 @ $996.90 |
You are here: research